Skip to Content

Notice

Importer of Controlled Substances Registration: Meridian Medical Technologies

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

ACTION:

Notice of registration.

SUMMARY:

Meridian Medical Technologies applied to be registered as an importer of a certain basic class of narcotic controlled substance. The DEA grants Meridian Medical Technologies registration as an importer of this controlled substance.

End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

By notice dated April 21, 2014, and published in the Federal Register on April 28, 2014, 79 FR 23374, Meridian Medical Technologies, 2555 Hermelin Drive, St. Louis, Missouri 63144, applied to be registered as an importer of a certain basic class of controlled substance. No comments or objections were submitted for this notice.

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of Meridian Medical Technologies to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above-named company is granted registration as an importer of morphine (9300), a basic class of narcotic controlled substance listed in schedule II.

The company manufactures a product containing morphine in the United States. The company exports this product to customers around the world. The company has been asked to ensure that its product, which is sold to European customers, meets the standards established by the European Pharmacopeia, administered by the Directorate for the Quality of Medicines (EDQM). In order to ensure that its product will meet European specifications, the company seeks to import morphine supplied by EDQM for use as reference standards.

This is the sole purpose for which the company will be authorized by the DEA to import morphine.

Start Signature

Dated: July 7, 2014.

Joseph T. Rannazzisi,

Deputy Assistant Administrator.

End Signature End Supplemental Information

[FR Doc. 2014-16318 Filed 7-11-14; 8:45 am]

BILLING CODE 4410-09-P